SEATTLE, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer, today announced the appointment of Dr. Arezoo Mirad as Senior Medical Director.
"We are excited to welcome Dr. Mirad to Atossa and look forward to leveraging her extensive experience in the clinical development of oncology candidates to further accelerate our (Z)-endoxifen development program," said Dr. Steven Quay, CEO and Chairman of Atossa Therapeutics. "With four ongoing Phase 2 trials in three distinct settings, several years of working capital and important data expected in 2024, we are well positioned to achieve our goal of meaningfully improving the current standard of care for cancer patients."
Prior to joining Atossa, Dr. Mirad served as Medical Director for Corcept Therapeutics, a commercial-stage biotech engaged in the discovery and development of medications to treat severe endocrine, oncology, metabolism and neurology disorders. In this role she acted as the lead medical monitor for global phase 2 and 3 registrational oncology clinical trials, led global site selection, and oversaw regulatory interactions. Dr. Mirad previously served as Medical Director for Alkermes, a fully integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. In this role, she oversaw a multi-center phase 3 registrational clinical trial and developed clinical trial designs for gynecologic & aerodigestive tract tumors.
Earlier in her career, Dr. Mirad oversaw the clinical development of a peptide-based mRNA vaccine for COVID-19 while serving as Medical Director for Silicon DynamiX and served as Chief Research Analyst at the University of Colorado, where she received her M.D. She also received a M.S. in Mathematics from The University of North Carolina at Charlotte.
"(Z)-endoxifen is a ...